Masahiko Kondo

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study

Kaoru Tsuchiya, Masayuki Kurosaki, Azusa Sakamoto et al. · Cancers · 2021 · 56 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma

Hironori Ochi, Masayuki Kurosaki, Kouji Joko et al. · Hepatology Research · 2022 · 45 citations · Full text

Medicine, Oncology, Pharmacology +12

Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus

Nobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui et al. · Clinical Infectious Diseases · 2020 · 43 citations · Full text

Medicine, Oncology, Hepatology +16

Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group

Toshifumi Tada, Masayuki Kurosaki, Shinichiro Nakamura et al. · Journal of Medical Virology · 2021 · 33 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group

Takehiro Akahane, Masayuki Kurosaki, Jun Itakura et al. · Hepatology Research · 2018 · 32 citations

Pharmacy, Infectious Diseases, Hepatic Pharmacotherapy +16